Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
UROKINASE RECEPTOR IN BREAST-CANCER TISSUE-EXTRACTS - ENZYME-LINKED-IMMUNOSORBENT-ASSAY WITH A COMBINATION OF MONOCLONAL AND POLYCLONAL ANTIBODIES
Autore:
RONNE E; HOYERHANSEN G; BRUNNER N; PEDERSEN H; RANK F; OSBORNE CK; CLARK GM; DANO K; GRONDAHLHANSEN J;
Indirizzi:
RIGSHOSP,FINSEN LAB,STRANDBLVD 49 DK-2100 COPENHAGEN O DENMARK BISPEBJERG HOSP,DEPT PATHOL DK-2400 COPENHAGEN DENMARK UNIV TEXAS,HLTH SCI CTR,DEPT MED,DIV ONCOL SAN ANTONIO TX 78284
Titolo Testata:
Breast cancer research and treatment
fascicolo: 3, volume: 33, anno: 1995,
pagine: 199 - 207
SICI:
0167-6806(1995)33:3<199:URIBT->2.0.ZU;2-7
Fonte:
ISI
Lingua:
ENG
Soggetto:
PLASMINOGEN ACTIVATION SYSTEM; LIGAND-BINDING DOMAIN; CELL-SURFACE RECEPTOR; INHIBITOR PAI-1; GLYCOSYL-PHOSPHATIDYLINOSITOL; MONOCLONAL-ANTIBODY; PURIFICATION; POTENTIATION; MEMBRANES; PROTEIN;
Keywords:
BREAST CANCER; ELISA; INVASION; PLASMINOGEN ACTIVATOR; UROKINASE RECEPTOR;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
37
Recensione:
Indirizzi per estratti:
Citazione:
E. Ronne et al., "UROKINASE RECEPTOR IN BREAST-CANCER TISSUE-EXTRACTS - ENZYME-LINKED-IMMUNOSORBENT-ASSAY WITH A COMBINATION OF MONOCLONAL AND POLYCLONAL ANTIBODIES", Breast cancer research and treatment, 33(3), 1995, pp. 199-207

Abstract

Urokinase plasminogen activator (uPA) is a proteolytic enzyme involved in degradation of the extracellular matrix during cancer invasion. The levels of uPA and its inhibitor PAI-1 in tumor extracts have previously been demonstrated to be of prognostic value in breast cancer as well as other types of cancer. We have previously characterized a specific cell surface receptor for uPA (uPAR) which strongly enhances the catalytic activity of uPA and is expressed during mammary cancer invasion. In order to quantitate uPAR in breast cancer tissue, we have now developed a sensitive enzyme-linked immunosorbent assay (ELISA), with polyclonal catching antibodies and three monoclonal detecting antibodies. The detection limit of the assay is approximately 0.16 fmol of uPARin a volume of 100 mu l (1.6 pM). There is a linear relationship between signal and uPAR concentration up to at least 6.6 fmol per 100 mu l(66 pM). Both free uPAR and uPAR in complex with uPA is detected. Therecovery of an internal uPAR standard in breast cancer tissue extracts is above 87%. The intra-assay and inter-assay variation coefficientsare 7% and 13%. In order to find a suitable buffer for extraction of various components of the uPA-system from breast cancer tissue, we tested buffers which previously have been used for optimal extraction of estrogen receptor (A), uPA (B), and uPAR (C). Buffer A and B extractedapproximately 30% and 50%, respectively, of the amount of uPAR extracted with buffer C. Extracts of samples of breast cancer tissue from 94patients all contained uPAR in amounts above the detection limit of the present assay, which appears suitable for studies of the potential prognostic value of uPAR in this disease. Significant correlations were found between uPAR, uPA and PAI-1 tumor levels.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 11/07/20 alle ore 17:11:13